Short answer
Medline Inc (MDLN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Medline’s Q3 and first-nine-month results released for period ended September 26, 2026.
Medline Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Medline’s Q3 and first-nine-month results released for period ended September 26, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, margins and outlook details
Item EX-99.1 · Exhibit EX-99.1
- Q3 net sales $7.9B, up 10.4%, while net income fell 1.2% to $318M, signaling growth with margin pressure
- Q3 Adjusted EBITDA $960M, up 11.8%, but gross margin declined to 24.5% from 26.4%
- Nine-month net income down 28.8% to $696M, burdened by $316M in Tracy fire losses and higher operating costs
- Organic Sales guidance raised to 10.0%-10.5%, while Adjusted EBITDA guidance remains $3.3B-$3.4B
- $1B share repurchase authorized alongside $750M repayment of the 2033 Refinancing Term Loan Facility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Medline Inc 8-K filings
Get the next MDLN 8-K as it lands
Follow MDLN for push alerts, or ask the research agent what this filing means.